Project Grant R21AR088206
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $396K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University $148,062 on September 30, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research investigates the mechanism by which epithelial stem and progenitor cells encode inflammatory memory in psoriasis and other remitting-relapsing inflammatory disorders. The study tests whether homeostatic and inflammatory transcription factors dynamically...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of Colorado $578,289 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846, Assistance Listing R01AR086835). The award funds translation and validation of DualMRI (Displacements Under Applied Loading by MRI), a noninvasive imaging method to measure articular cartilage biomechanics and predict pre-osteoarthritis pathogenesis in...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Rush University Medical Center $643,185 on June 10, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds development of validated, patient-specific computational models to predict polyethylene wear in total shoulder arthroplasty (TSA) and identify modifiable surgical, design, and rehabilitation targets to improve implant...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $547,767 to the University of Rochester on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate host mechanisms governing Staphylococcus aureus persistence during implant-associated osteomyelitis. The research uses humanized mouse models and multi-omic analysis of human T cells to understand why some patients resolve acute bone infections while others...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $117,426 to the University of California, San Diego on June 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a noninvasive MRI method for assessing bone quality in type 2 diabetes patients. The project develops an ultrashort echo time quantitative magnetization transfer (UTE-QMT) MRI technique to measure collagen crosslinking in cortical bone, a bone quality...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Johns Hopkins University $569,402 on July 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate clinical heterogeneity in immune checkpoint inhibitor-induced inflammatory arthritis. The recipient will conduct prospective clinical studies leveraging the RADIOS (Rheumatology Adverse Events due to Immunotherapy Observational Study) cohort, a multicenter USA...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $1.696 million to Poly Orth International on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds translational pre-clinical research and development of a 3D-printed skin and bone integrated pylon (SBIP-3D) for direct skeletal attachment of limb prostheses. The technology, developed by Poly Orth International, integrates with both residual bone...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the Hospital for Special Surgery Fund, Inc. (doing business as HSS Foundation) $473,752 on September 16, 2025, for research developing a circulating cell-free tumor DNA (ctDNA) biomarker to assess immunosuppressive drug safety in patients with immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Carnegie Mellon University $486,545 on July 3, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate in vivo cartilage mechanics as a sensitive biomarker for early knee osteoarthritis detection. The research establishes a novel metric based on cartilage deformation and composition changes in response to common physical...